Table 5.
TGF-β regulated genes (38) in A549 involved in MAP kinase signalling
| Acc No | DAVID Gene Name | 1 hr | 4 hr | 12 hr |
| H09832 | ACTIVIN A RECEPTOR, TYPE IB | 1.01 ± 0.17 | 1.66 ± 0.29 | 1.17 ± 0.06 |
| N27681 | HEAT SHOCK 70 KDA PROTEIN 1A | 1.12 ± 0.01 | 1.46 ± 0.18 | 1.42 ± 0.08 |
| H73255 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 6 | 0.84 ± 0.31 | 1.04 ± 0.07 | 1.49 ± 0.11 |
| N42722 | GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), GAMMA 12 | 1.44 ± 0.04 | 1.5 ± 0.09 | 1.28 ± 0.17 |
| AA039598 | RIBOSOMAL PROTEIN S6 KINASE, 90 KDA, POLYPEPTIDE 1 | 1.16 ± 0.13 | 1.21 ± 0.02 | 1.32 ± 0.02 |
| AA030029 | PROTEIN KINASE C, ALPHA | 1.33 ± 0.23 | 1.56 ± 0.08 | 1.36 ± 0.03 |
| H73472 | CELL DIVISION CYCLE 42 (GTP BINDING PROTEIN, 25 KDA) | 1.24 ± 0.27 | 1.33 ± 0.07 | 1.56 ± 0.01 |
| H62639 | HEAT SHOCK 70 KDA PROTEIN 8 | 1.29 ± 0.01 | 1.68 ± 0.18 | 1.37 ± 0 |
| H23019 | TRANSFORMING GROWTH FACTOR, BETA RECEPTOR I (ACTIVIN A RECEPTOR TYPE II-LIKE KINASE, 53 KDA) | 1.09 ± 0.01 | 2.53 ± 0.07 | 2.11 ± 0.41 |
| AA088648 | FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME) | 1.45 ± 0.24 | 1.97 ± 0.08 | 1.77 ± 0.09 |
| AV747676 | V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 3 (PROTEIN KINASE B, GAMMA) | 1.06 ± 0.13 | 1.46 ± 0.05 | 1.18 ± 0.01 |
| AI500475 | RAS GUANYL RELEASING PROTEIN 1 (CALCIUM AND DAG-REGULATED) | 1.31 ± 0.05 | 1.37 ± 0 | 1.41 ± 0.07 |
| R86053 | NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B-CELLS 2 (P49/P100) | 0.99 ± 0.12 | 0.9 ± 0.07 | 1.44 ± 0.09 |
| BE502112 | RIBOSOMAL PROTEIN S6 KINASE, 90 KDA, POLYPEPTIDE 3 | 0.37 ± 0.1 | 0.29 ± 0.05 | 0.41 ± 0.06 |
| H23109 | FIBROBLAST GROWTH FACTOR 1 (ACIDIC) | 0.94 ± | 1.36 ± 0.01 | 1.13 ± 0.05 |
| AA127934 | PROTEIN KINASE, X-LINKED | 1.21 ± 0.07 | 1.38 ± 0.01 | 1.35 ± 0.07 |
| H89206 | PROTEIN KINASE, CAMP-DEPENDENT, CATALYTIC, BETA | 1.18 ± 0.08 | 1.42 ± 0.04 | 1.25 ± 0.03 |
| R14348 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 | 1.45 ± 0.09 | 1.22 ± 0.17 | 1.03 ± 0.06 |
| BM924824 | RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1 (RHO FAMILY, SMALL GTP BINDING PROTEIN RAC1) | 1.39 ± 0 | 1.41 ± 0.06 | 1.28 ± 0.18 |
| H11708 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4 | 1.38 ± 0.02 | 1.54 ± 0.1 | 1.24 ± 0.17 |
| R36401 | FILAMIN B, BETA (ACTIN BINDING PROTEIN 278) | 0.96 ± 0.02 | 1.17 ± 0.11 | 1.33 ± 0.01 |
| BI758537 | MADS BOX TRANSCRIPTION ENHANCER FACTOR 2, POLYPEPTIDE C (MYOCYTE ENHANCER FACTOR 2C) | 1.77 ± 0.42 | 1.25 ± | 1.36 ± 0.09 |
| W56249 | ACTIVATING TRANSCRIPTION FACTOR 2 | 1.25 ± 0.13 | 1.5 ± 0.02 | 1.72 ± 0.18 |
| AA034981 | INTERLEUKIN 1 RECEPTOR, TYPE I | 0.37 ± 0.08 | 0.4 ± 0.02 | 0.29 ± 0.04 |
| AA056664 | V-AKT MURINE THYMOMA VIRAL ONCOGENE HOMOLOG 1 | 1.34 ± 0.15 | 1.44 ± 0.05 | 1.36 ± 0.07 |
| H20677 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7 INTERACTING PROTEIN 1 | 1.13 ± 0.15 | 0.96 ± 0.1 | 1.6 ± 0.01 |
| BM999610 | V-JUN SARCOMA VIRUS 17 ONCOGENE HOMOLOG (AVIAN) | 1.57 ± 0.26 | 2.13 ± 0.01 | 1.66 ± 0.18 |
| BE781203 | CALCIUM CHANNEL, VOLTAGE-DEPENDENT, ALPHA 1G SUBUNIT | 1.13 ± 0.03 | 1.02 ± 0 | 1.44 ± 0 |
| T83272 | RAS P21 PROTEIN ACTIVATOR 2 | 0.96 ± 0.08 | 1.12 ± 0.18 | 1.33 ± 0.02 |
| T75436 | MITOGEN-ACTIVATED PROTEIN KINASE 10 | 1.16 ± 0.17 | 1.22 ± 0.05 | 1.37 ± 0.07 |
| W70006 | CELL DIVISION CYCLE 25B | 1.47 ± 0.1 | 1.15 ± 0.05 | 1.38 ± 0.08 |
| R32409 | PHOSPHOLIPASE A2, GROUP V | 1.14 ± 0.27 | 1.27 ± 0.01 | 1.5 ± 0.07 |
| AW961873 | CALCIUM CHANNEL, VOLTAGE-DEPENDENT, GAMMA SUBUNIT 4 | 1.45 ± 0.15 | 1.23 ± 0.17 | 1.02 ± 0 |
| BI752921 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR, BETA POLYPEPTIDE | 1.43 ± 0.09 | 1.03 ± 0.02 | 1.09 ± 0.07 |
| BQ055308 | RIBOSOMAL PROTEIN L4 | 1.44 ± 0.05 | 1.26 ± 0.04 | 1.43 ± 0.08 |
| R14058 | PROTEIN KINASE C, BETA 1 | 1.54 ± 0.06 | 1.08 ± 0.01 | 1.15 ± 0 |
| BQ016117 | V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG | 1.48 ± 0.26 | 1.44 ± 0.04 | 1.29 ± 0.06 |
| W05234 | CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA 3 SUBUNIT | 1.4 ± 0.07 | 1.15 ± 0.05 | 1.27 ± 0 |
The list in the table shows the regulated genes as revealed by the DAVID tool. The columns show Genbank accession no., gene name, and fold change with respect to untreated controls at 1 hr, 4 hr and 12 hr time points following TGF-β treatment respectively. The regulation shown against each gene is depicted as fold change ± S.E. with respect to untreated cells. Each experimental value of the duplicates of respective genes is shown in tables S1 and S2 (see additional files 1 and 2). The number in the parenthesis of the title represents the number of genes in the table.